What is the sandostatin octreoscan?

What is the Sandostatin Octreoscan?

The Sandostatin Octreoscan is a diagnostic imaging test that combines octreotide with a radioactive tracer to locate tumors that have somatostatin receptors on their surface. The agent is injected, then a gamma camera records where the tracer accumulates, producing images that help doctors identify neuroendocrine tumors and their spread.

How does the Octreoscan differ from a standard CT or MRI?

CT and MRI show anatomy. The Octreoscan shows function by highlighting cells that bind octreotide. It can detect small or hidden lesions that do not yet change organ shape, but its images are lower in resolution than CT or MRI, so clinicians often use both tests together.

What tumors is the scan most commonly used for?

It is ordered mainly for gastroenteropancreatic neuroendocrine tumors, carcinoid tumors, and some pituitary or paraganglioma cases. Because these tumors over-express somatostatin receptors, the scan can stage disease, guide surgery, and monitor response to somatostatin-analog therapy.

When does the scan require special preparation?

Patients stop short-acting octreotide 24 hours before the test and long-acting formulations at least four weeks prior, because the drug competes with the tracer for receptor binding. They also fast for several hours beforehand to reduce background uptake in the bowel.

Are there safety concerns or radiation exposure limits?

The procedure delivers a moderate radiation dose comparable to other nuclear-medicine studies. Pregnant patients are generally excluded, and breastfeeding must be interrupted for 48 hours after injection. Kidney function is checked because the tracer is cleared through the kidneys.

Who manufactures the Octreoscan kit?

The commercial kit was originally supplied by Mallinckrodt and is now distributed by Curium Pharma. [1]

When did the product receive FDA approval?

The Octreoscan kit was approved by the FDA in 1994 for imaging of somatostatin-receptor-positive tumors. [1]

What has replaced or supplemented the Octreoscan in recent years?

Gallium-68 DOTATATE PET/CT, marketed as Netspot, provides higher-resolution images and has largely supplanted the Octreoscan at many centers. The older indium-111 Octreoscan remains available for sites without PET capability.

Can the scan be used to predict response to Sandostatin therapy?

Uptake on the Octreoscan indicates the presence of somatostatin receptors and therefore suggests the tumor may respond to octreotide or lanreotide treatment. However, the scan is not a perfect predictor; some receptor-positive tumors still progress despite analog therapy.

[1] https://www.drugpatentwatch.com